Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
2024年5月1日 - 9:00PM
ビジネスワイヤ(英語)
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical
company dedicated to the development of innovative therapeutics to
treat seizure disorders, today announced that it plans to release
financial results for the first quarter ended March 31, 2024 before
market open on May 8, 2024.
The press release will be available on Marinus’ investor
relations website at
https://ir.marinuspharma.com/news/default.aspx.
About Marinus Pharmaceuticals
Marinus is a commercial-stage pharmaceutical company dedicated
to the development of innovative therapeutics for seizure
disorders. The Company first introduced FDA-approved prescription
medication ZTALMY® (ganaxolone) oral suspension CV in the U.S. in
2022 and continues to invest in the potential of ganaxolone in IV
and oral formulations to maximize therapeutic reach for adult and
pediatric patients in acute and chronic care settings. For more
information about Marinus visit www.marinuspharma.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240501512045/en/
Company Investors and Media
Molly Cameron Director, Corporate Communications & Investor
Relations Marinus Pharmaceuticals, Inc.
mcameron@marinuspharma.com
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 5 2024 まで 6 2024
Marinus Pharmaceuticals (NASDAQ:MRNS)
過去 株価チャート
から 6 2023 まで 6 2024